SCILEX (SCLX) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $70M

Market Cap: $56.2MFounded: 2013HQ: Palo Alto, United States

Sector Ranking#99 in Drug Delivery & Formulation #296 in Small Molecule Drugs

Overview

Scilex Holding Company (Nasdaq: SCLX) is a revenue-generating biopharmaceutical company dedicated to becoming a global leader in non-opioid pain management. Its strategy combines the commercialization of acquired, approved products like ZTlido®, Elyxyb®, and Gloperba® with the development of a proprietary pipeline, including the late-stage injectable candidate SEMDEXA™ for sciatica. Founded in 2013 and headquartered in Palo Alto, California, Scilex is positioned at the critical intersection of drug delivery innovation and the urgent societal need to address the opioid crisis.

Pain ManagementNeurology

Technology Platform

Proprietary drug delivery systems for topical patches (enhanced adhesion/diffusion) and oral solutions (fast-acting, precision dosing), focused on optimizing non-opioid analgesics.

Funding History

2

Total raised:$70M

Series B$50MVickers Venture PartnersMar 15, 2023

Series A$20MVickers Venture PartnersJun 15, 2021

Opportunities

The urgent need for non-opioid pain alternatives creates a massive, sustained market.

SEMDEXA™ has first-in-class potential in the sciatica injection market, and the commercial portfolio provides a revenue base to fund pipeline growth.

Risk Factors

Commercial success is unproven in crowded markets.

The late-stage pipeline carries regulatory risk, and the company's low market cap and strategic financial moves introduce complexity and potential distraction.

Competitive Landscape

Highly competitive across all indications, facing both branded and generic drugs. Scilex's edge is based on superior drug delivery rather than novel mechanisms, requiring strong commercialization to demonstrate differentiated value.